FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313334517> ?p ?o ?g. }

• W4313334517 endingPage "165" @default.
• W4313334517 startingPage "155" @default.
• W4313334517 abstract "Background Regional hyperthermia (RHT) with cisplatin added to gemcitabine showed efficacy in gemcitabine-pre-treated patients with advanced pancreatic ductal adenocarcinoma. We conducted a randomised clinical trial to investigate RHT with cisplatin added to gemcitabine (GPH) compared with gemcitabine (G) in the adjuvant setting of resected pancreatic ductal adenocarcinoma. Methods This randomised, multicentre, open-label trial randomly assigned patients to either GPH (gemcitabine 1000 mg/m2 on day 1, 15 and cisplatin 25 mg/m2 with RHT on day 2, 3 and 15,16) or to G (gemcitabine 1000 mg/m2 on day 1,8,15), four-weekly over six cycles. Disease-free survival (DFS) was the primary end-point. Secondary end-points included overall survival (OS) and safety. Results A total of 117 eligible patients (median age, 63 years) were randomly allocated to treatment (57 GPH; 60 G). With a follow-up time of 56.6 months, the median DFS was 12.7 compared to 11.2 months for GPH and G, respectively (p = 0.394). Median post-recurrence survival was significantly prolonged in the GPH-group (15.3 versus 9.8 months; p = 0.031). Median OS reached 33.2 versus 25.2 months (p = 0.099) with 5-year survival rates of 28.4% versus 18.7%. Excluding eight patients who received additional capecitabine in the G-arm (investigators choice), median OS favoured GPH (p = 0.052). Adverse events CTCAE (Common Terminology Criteria for Adverse Events) grade ≥3 occurred in 61.5% (GPH) versus 63.6% (G) of patients. Two patients in the G-group died because of treatment-related toxic effects. Conclusions The randomised controlled Hyperthermia European Adjuvant Trial study failed to demonstrate a significant difference in DFS. However, it suggests a difference in post-recurrence survival and a trend for improved OS. ClinicalTrials gov, number NCT01077427." @default.
• W4313334517 created "2023-01-06" @default.
• W4313334517 creator A5001814278 @default.
• W4313334517 creator A5002463670 @default.
• W4313334517 creator A5006770956 @default.
• W4313334517 creator A5006886614 @default.
• W4313334517 creator A5008188449 @default.
• W4313334517 creator A5010368219 @default.
• W4313334517 creator A5011844200 @default.
• W4313334517 creator A5011919158 @default.
• W4313334517 creator A5012985925 @default.
• W4313334517 creator A5013091774 @default.
• W4313334517 creator A5013965318 @default.
• W4313334517 creator A5016828351 @default.
• W4313334517 creator A5017861385 @default.
• W4313334517 creator A5018202963 @default.
• W4313334517 creator A5019472911 @default.
• W4313334517 creator A5024418859 @default.
• W4313334517 creator A5024665791 @default.
• W4313334517 creator A5027231637 @default.
• W4313334517 creator A5028333961 @default.
• W4313334517 creator A5028938155 @default.
• W4313334517 creator A5029197290 @default.
• W4313334517 creator A5031266401 @default.
• W4313334517 creator A5034065380 @default.
• W4313334517 creator A5045027232 @default.
• W4313334517 creator A5048170384 @default.
• W4313334517 creator A5048356727 @default.
• W4313334517 creator A5048582993 @default.
• W4313334517 creator A5052417750 @default.
• W4313334517 creator A5057302175 @default.
• W4313334517 creator A5059517063 @default.
• W4313334517 creator A5062356887 @default.
• W4313334517 creator A5062761846 @default.
• W4313334517 creator A5064932488 @default.
• W4313334517 creator A5067125554 @default.
• W4313334517 creator A5072612103 @default.
• W4313334517 creator A5074202356 @default.
• W4313334517 creator A5074975947 @default.
• W4313334517 creator A5075877427 @default.
• W4313334517 creator A5077645915 @default.
• W4313334517 creator A5083695901 @default.
• W4313334517 creator A5084868534 @default.
• W4313334517 creator A5085883112 @default.
• W4313334517 date "2023-03-01" @default.
• W4313334517 modified "2023-10-18" @default.
• W4313334517 title "Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial" @default.
• W4313334517 cites W1572554526 @default.
• W4313334517 cites W1968812902 @default.
• W4313334517 cites W2037393203 @default.
• W4313334517 cites W2039919944 @default.
• W4313334517 cites W2066364033 @default.
• W4313334517 cites W2073074450 @default.
• W4313334517 cites W2101141939 @default.
• W4313334517 cites W2101465269 @default.
• W4313334517 cites W2107780185 @default.
• W4313334517 cites W2128668604 @default.
• W4313334517 cites W2129197203 @default.
• W4313334517 cites W2156124327 @default.
• W4313334517 cites W2158397794 @default.
• W4313334517 cites W2262412618 @default.
• W4313334517 cites W2289016838 @default.
• W4313334517 cites W2581973599 @default.
• W4313334517 cites W2746266812 @default.
• W4313334517 cites W2765730870 @default.
• W4313334517 cites W2770244022 @default.
• W4313334517 cites W2787945010 @default.
• W4313334517 cites W2801077576 @default.
• W4313334517 cites W2903623792 @default.
• W4313334517 cites W2953173394 @default.
• W4313334517 cites W2994968861 @default.
• W4313334517 cites W3018537461 @default.
• W4313334517 cites W3207348852 @default.
• W4313334517 doi "https://doi.org/10.1016/j.ejca.2022.12.009" @default.
• W4313334517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36657324" @default.
• W4313334517 hasPublicationYear "2023" @default.
• W4313334517 type Work @default.
• W4313334517 citedByCount "1" @default.
• W4313334517 crossrefType "journal-article" @default.
• W4313334517 hasAuthorship W4313334517A5001814278 @default.
• W4313334517 hasAuthorship W4313334517A5002463670 @default.
• W4313334517 hasAuthorship W4313334517A5006770956 @default.
• W4313334517 hasAuthorship W4313334517A5006886614 @default.
• W4313334517 hasAuthorship W4313334517A5008188449 @default.
• W4313334517 hasAuthorship W4313334517A5010368219 @default.
• W4313334517 hasAuthorship W4313334517A5011844200 @default.
• W4313334517 hasAuthorship W4313334517A5011919158 @default.
• W4313334517 hasAuthorship W4313334517A5012985925 @default.
• W4313334517 hasAuthorship W4313334517A5013091774 @default.
• W4313334517 hasAuthorship W4313334517A5013965318 @default.
• W4313334517 hasAuthorship W4313334517A5016828351 @default.
• W4313334517 hasAuthorship W4313334517A5017861385 @default.
• W4313334517 hasAuthorship W4313334517A5018202963 @default.
• W4313334517 hasAuthorship W4313334517A5019472911 @default.
• W4313334517 hasAuthorship W4313334517A5024418859 @default.
• W4313334517 hasAuthorship W4313334517A5024665791 @default.
• W4313334517 hasAuthorship W4313334517A5027231637 @default.
• W4313334517 hasAuthorship W4313334517A5028333961 @default.

• next